Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caelyx and Carboplatin in Relapsed Epithelial Ovarian Cancer
NCT00780039Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2003
- Primary completion
- Sep 2007
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in epithelial ovarian cancer (EOC), sponsored by Merck & Co. Primary endpoints: Complete Response Rate at 1 year and Partial Response Rate at 1 year. Started Oct 2003; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT00780039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00780039.